fisogatinib (BLU-554) / Blueprint Medicines, CStone Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fisogatinib (BLU-554) / Blueprint Medicines
NCT04194801: A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Completed
1/2
26
RoW
Phase Ib: Fisogatinib (BLU-554) 400mg in combination with Sugemalimab (CS1001) 1200mg, Phase Ib: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg, Phase II: Fisogatinib (BLU-554) 600mg in combination with Sugemalimab (CS1001) 1200mg
CStone Pharmaceuticals, Blueprint Medicines Corporation
Hepatocellular Carcinoma
10/21
10/21

Download Options